Medi-Physics' Ceretec imaging agent launch set for in mid-June for detecting infections.
MEDI-PHYSICS CERETEC NEW FORMULATION WILL BE LAUNCHED at the Society of Nuclear Medicine's annual meeting June 12-15 in Minneapolis. Three improvements of the diagnostic imaging agent Ceretec (technetium Tc99m exametazime) were approved April 7 through two efficacy supplements. The new formulation of Ceretec will replace the original version that was approved by FDA in December 1988 for stroke imaging with single photon emission computed tomography, Medi-Physics said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth